Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 49 | ECE2017 | Next issue

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

Card image cap
20-23 May 2017, Lisbon, Portugal Further information

Oral Communications

Pituitary Clinical

ea0049oc12.1 | Pituitary Clinical | ECE2017

T2-Weighted signal intensity of functional pituitary adenomas: correlation with clinicopathological findings and response to treatment

Dogansen Sema Ciftci , Tanrikulu Seher , Yalin Gulsah Yenidunya , Tekin Sakin , Nizam Nihan , Bilgic Bilge , Yarman Sema

Purpose: Somatotrophinomas have been shown to demonstrate T2-weighted signal intensity (WSI) on MRI that is correlated with clinicopathological findings and response to treatment. Therefore, we aimed to investigate these correlations in functional pituitary adenomas, including prolactinoma and corticotrophinoma. Material and MethodsPatients with somatotrophinoma (n=87), prolactinoma (n=78) and corticotrophinoma (n=33) were invo...

ea0049oc12.2 | Pituitary Clinical | ECE2017

Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: Results from a European Society of Endocrinology (ESE) survey

McCormack Ann , Dekkers Olaf M , Petersenn Stephan , Popovic Vera , Trouillas Jacqueline , Raverot Gerald , Burman Pia

Objective: To collect clinical and treatment outcome data in a large patient cohort, and specifically to report experience with temozolomide (TMZ).Design: Cohort study based on an electronic survey open for participation to ESE members Dec 2015-Nov 2016.Results: Reports on 167 patients, 40 pituitary carcinomas, and 127 aggressive pituitary tumours were obtained. Median age at diagnosis was 43 (range 4–79) years. 59% of tumours...

ea0049oc12.3 | Pituitary Clinical | ECE2017

Recombinant Growth Hormone added to physical therapy in GH-deficient adults with complete (ASIA A) Spine Injury (EudraCT 2011-005377-23)

Cuatrecasas Guillem , Kumru Hatice , Coves M°Josep , Patrascioiu Ioana , Vidal Josep

Introduction: Although in-vitro models suggest GH-induced differentiation, migration and survival of astrocytes and oligodendrocytes, no studies had been published in-vivo. We want to evaluate the efficacy and safety of GH associated with physical therapy compared to placebo in patients with complete spine injury (SI) and associated GH deficiency (GHD).Methods: Eighteen Patients with complete SI were screened for GHD (glucagon test). 12 severe (...

ea0049oc12.4 | Pituitary Clinical | ECE2017

Subclinical cardiovascular system dysfunction in the patients with Cushing’s disease

Witek Przemyslaw , Uzieblo-Zyczkowska Beata , Krzesinski Pawel , Jurek Agnieszka , Zielinski Grzegorz , Skrobowski Andrzej , Gielerak Grzegorz

Background: Hypercortisolism in Cushing’s disease (CD) is associated with high cardiovascular risk. Hemodynamic disturbances, especially excessive vasoconstriction and elevated blood pressure (BP), may contribute to accelerated myocardial remodeling. Early identification of subclinical left ventricular (LV) dysfunction may be crucial for optimizing treatment and reducing mortality in patients with CD.Purpose: The aim of this study was to assess the ...

ea0049oc12.5 | Pituitary Clinical | ECE2017

Effects of pegvisomant and somatostatin receptor ligands on risk of vertebral fractures in patients with Acromegaly

Chiloiro Sabrina , Mazziotti Gherardo , Giampietro Antonella , Formenti Anna Maria , Bianchi Antonio , Mormando Marilda , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Acromegalic osteopathy is an emerging complication of chronic GH excess characterized by increase in bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). Medical therapies may exert direct effects on peripheral targets leading to improvement of clinical outcomes regardless of biochemical control of acromegaly. In this longitudinal study, we compared the effects pegvisomant (PegV) and somatostatin receptor ligands (SRLs) on VF risk ...